BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sadowski SM, Pieterman CRC, Perrier ND, Triponez F, Valk GD. Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature. Endocr Relat Cancer 2020;27:R145-61. [PMID: 32229700 DOI: 10.1530/ERC-19-0372] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Müller-debus C, Wellner U, Keck T. Sporadische duodenale neuroendokrine Neoplasien. Springer Reference Medizin 2023. [DOI: 10.1007/978-3-662-63317-5_41] [Reference Citation Analysis]
2 Albers MB, Manoharan J, Bartsch DK. Hereditäre duodenopankreatische neuroendokrine Neoplasien. Springer Reference Medizin 2023. [DOI: 10.1007/978-3-662-63317-5_45] [Reference Citation Analysis]
3 Russo A, Gangi A. The Evolving Landscape of Neuroendocrine Tumors. Surg Oncol Clin N Am 2023;32:185-98. [PMID: 36410917 DOI: 10.1016/j.soc.2022.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Liu JB, Cai J, Dhir M, Paniccia A, Zureikat AH, Ramonell KM, McCoy KL, Carty SE, Yip L. Long-Term Outcomes for Patients with Multiple Endocrine Neoplasia Type 1 and Duodenopancreatic Neuroendocrine Neoplasms. Ann Surg Oncol 2022. [PMID: 35963905 DOI: 10.1245/s10434-022-12350-1] [Reference Citation Analysis]
5 Ye J, Wu H, Li J, Liu C. Impact of Surgery on Non-Functional Pancreatic Neuroendocrine Tumors ≤2 cm: Analyses With Propensity Score–Based Inverse Probability of Treatment Weighting. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.890564] [Reference Citation Analysis]
6 Ishida H, Lam AK. Pancreatic Neuroendocrine Neoplasms: Updates on Genomic Changes in Inherited Tumour Syndromes and Sporadic Tumours Based on WHO Classification. Crit Rev Oncol Hematol 2022;:103648. [PMID: 35248713 DOI: 10.1016/j.critrevonc.2022.103648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Müller-debus C, Wellner U, Keck T. Sporadische duodenale neuroendokrine Neoplasien. Springer Reference Medizin 2022. [DOI: 10.1007/978-3-662-61724-3_41-1] [Reference Citation Analysis]
8 Albers MB, Manoharan J, Bartsch DK. Hereditäre duodenopankreatische neuroendokrine Neoplasien. Springer Reference Medizin 2022. [DOI: 10.1007/978-3-662-61724-3_45-1] [Reference Citation Analysis]
9 Kassi E, Kaltsas G. Plasma polyamines as an additional to imaging biomarker in MEN1 patients with duodenopancreatic neuroendocrine tumors. J Clin Endocrinol Metab 2021:dgab683. [PMID: 34543418 DOI: 10.1210/clinem/dgab683] [Reference Citation Analysis]
10 Soczomski P, Jurecka-Lubieniecka B, Krzywon A, Cortez AJ, Zgliczynski S, Rogozik N, Oczko-Wojciechowska M, Pawlaczek A, Bednarczuk T, Jarzab B. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations. Front Endocrinol (Lausanne) 2021;12:681013. [PMID: 34122352 DOI: 10.3389/fendo.2021.681013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Calissendorff J, Bjellerup-Calissendorff F, Bränström R, Juhlin CC, Falhammar H. Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center. Front Endocrinol (Lausanne) 2021;12:657698. [PMID: 33927695 DOI: 10.3389/fendo.2021.657698] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Chatani PD, Agarwal SK, Sadowski SM. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2020;11:575620. [PMID: 33537001 DOI: 10.3389/fendo.2020.575620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ito T, Masui T, Komoto I, Doi R, Osamura RY, Sakurai A, Ikeda M, Takano K, Igarashi H, Shimatsu A, Nakamura K, Nakamoto Y, Hijioka S, Morita K, Ishikawa Y, Ohike N, Kasajima A, Kushima R, Kojima M, Sasano H, Hirano S, Mizuno N, Aoki T, Aoki T, Ohtsuka T, Okumura T, Kimura Y, Kudo A, Konishi T, Matsumoto I, Kobayashi N, Fujimori N, Honma Y, Morizane C, Uchino S, Horiuchi K, Yamasaki M, Matsubayashi J, Sato Y, Sekiguchi M, Abe S, Okusaka T, Kida M, Kimura W, Tanaka M, Majima Y, Jensen RT, Hirata K, Imamura M, Uemoto S. JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. J Gastroenterol 2021;56:1033-44. [PMID: 34586495 DOI: 10.1007/s00535-021-01827-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
14 Brandi ML, Agarwal SK, Perrier ND, Lines KE, Valk GD, Thakker RV. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev 2021;42:133-70. [PMID: 33249439 DOI: 10.1210/endrev/bnaa031] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
15 Cloyd JM, Poultsides GA. The Landmark Series: Pancreatic Neuroendocrine Tumors. Ann Surg Oncol 2021;28:1039-49. [PMID: 32948965 DOI: 10.1245/s10434-020-09133-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]